Akebia Therapeutics, Inc. revised revenue guidance for the year 2023. The company slightly lowered Auryxia net product revenue guidance to $170 million - $175 million for 2023 from $175 million - $180 million due to an unfavorable impact from market dynamics, volume and payor mix.